Why the study?
Current oral anticoagulants carry bleeding concerns that often dictate treatment decisions, whereas factor XIa inhibition may selectively inhibit coagulation without significantly impacting hemostasis.
Does asundexian provide a safe and effective option for thrombosis prevention and treatment with less bleeding compared to available anticoagulants?
Does asundexian provide a safe and effective option for thrombosis prevention and treatment with less bleeding compared to available anticoagulants?
Asundexian is a novel oral factor XIa inhibitor currently under investigation that may offer effective thrombosis prevention with a lower risk of bleeding compared to standard anticoagulants.
May support phase 2 development of factor XIa inhibitors; leaves open clinical role pending randomized trials.
Oral anticoagulants, including warfarin and direct oral anticoagulants, are the standard of care for thrombosis prevention and treatment; however, concerns of bleeding often dictate treatment decisions. Inhibition of the intrinsic coagulation system via factor XIa may allow for selective inhibition of the coagulation cascade without significantly impacting hemostasis after injury. Asundexian is an oral small molecule factor XIa inhibitor that, via this novel mechanism, may prove to be a safe and effective option compared with available anticoagulants. Early clinical data for asundexian was promising as a safer alternative to current therapies and prompted further analysis in certain patient populations at increased thrombotic risk. Currently, studies are ongoing to evaluate the safety and efficacy in stroke prevention in atrial fibrillation and in patients following an acute noncardioembolic ischemic stroke or high-risk transient ischemic attack.
No takes yet. Share an insight, caveat, or question.
D'Allesandro et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: